This retrospective, cross-sectional study evaluated whether HIV-infected patients received aspirin and statins for the primary prevention of myocardial infarction and stroke. Among the 258 patients included, 50.4% (n = 130/258) of the patients had a high risk of myocardial infarction and 14% (n = 36/258) of stroke. Overall, 43.1% (n = 56/130) and 50% (n = 18/36) of the patients were prescribed aspirin for the primary prevention of myocardial infarction and stroke, respectively. Among the patients who required statin therapy, 42.5% (n = 34/80) and 37.1% (n = 13/35) of patients received it for the primary prevention of myocardial infarction and stroke, respectively. The patients who had hypertension (odds ratio 3.8, 95% confidence interval 1.5–10.9) and diabetes mellitus (odds ratio 5.6, 95% confidence interval 2.6–12.4) were more likely to receive aspirin. Interventions are needed to improve provider awareness of the use of aspirin and statins in the primary prevention of myocardial infarction and stroke in HIV-infected patients.
LangSMary-KrauseMCotteL. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS2010; 24: 1228–1230.
2.
FreibergMSChangCCKullerLH. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med2013; 173: 614–622.
3.
SenSRabinsteinAAElkindMSV. Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovasc Dis2012; 33: 209–218.
4.
Caron-DebarleMLagathuCBoccaraF. HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med2010; 16: 218–229.
5.
TriantVALeeHHadiganC. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab2007; 92: 2506–2512.
6.
AnuuradESemradABerglundL. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord2009; 7: 401–410.
7.
DubeMPLipshultzSTFichtenbaumCJ. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation2008; 118: e35–e40.
8.
LichtensteinKAArmonCBuchaczK. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis2010; 51: 435–337.
9.
KaplanRCKingsleyLASharrettAR. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis2007; 45: 1074–1081.
10.
LangSMary-KrauseMCotteL. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med2010; 170: 1228–1238.
11.
WormSWSabinCWeberR. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis2010; 201: 318–330.
12.
MonforteAdReissPRyomL. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS2013; 27: 407–415.
13.
UcciferriCFalascaKVignaleF. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. J Med Virol2013; 85: 755–759.
14.
D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet2008; 371: 1417–1426.
15.
CrucianiMZanivehelliVSerpelloniG. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS2011; 25: 1993–2004.
16.
d’ArminioASabinCAPhillipsAN. Cardio- and cerebrovascular events in HIV-infected persons. AIDS2004; 18: 1811–1817.
17.
SubsaiKKanoksriSSiwapornC. Neurological complications in AIDS patients receiving HAART: a 2-year retrospective study. Eur J Neurol2006; 13: 233–239.
18.
BozzetteSAAkeCFTamHK. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med2003; 348: 702–710.
19.
CorralIQueredaCMorenoA. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors. Cerebrovasc Dis2009; 27: 559–563.
20.
Preventive Services Task ForceUS. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2009; 150: 396–404.
21.
GoldsteinLBBushnellCDAdamsRJ. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2011; 42: 517–584.
22.
ReinschNNeuhausKEsserS. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART Study. Eur J Cardiovasc Prev Rehabil2012; 19: 267–274.
23.
TorneroCVenturaAMafeM. Aspirin is indicated for primary prevention of cardiovascular disease in HIV-infected patients. J Acquir Immune Defic Syndr2010; 54: 560–560.
24.
BurkholderGATamhaneARSalinasJL. Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infect Dis2012; 55: 1550–1557.
25.
CareyKMComeeMRDonovanJL. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Ann Pharmacother2012; 46: 688–695.
26.
HennekensCHSacksFMTonkinA. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med2004; 164: 40–44.
27.
StoneNJRobinsonJLichtensteinAH. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2013; 00: 000–000.
28.
GoldsteinLBBushnellCDAdamsRJ. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2011; 42: 517–584.
29.
ShermanBWLynchWD. The association of smoking with medical treatment adherence in the workforce of a large employer. Patient Prefer Adherence2014; 8: 477–486.
30.
HerlitzJTothPPNaesdalJ. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs2010; 10: 125–141.
31.
ParraSCollBAragonesG. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med2010; 11: 225–231.
32.
Serrano-VillarSEstradaVGomez-GarreD. Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms. Eur J Prev Cardiol2012; 21: 739–748.
